M&A Deal Summary

Currax Pharmaceuticals Acquires Nalpropion Pharmaceuticals

On September 27, 2019, Currax Pharmaceuticals acquired life science company Nalpropion Pharmaceuticals

Acquisition Highlights
  • This is Currax Pharmaceuticals’ 2nd transaction in the Life Science sector.
  • This is Currax Pharmaceuticals’ 2nd transaction in the United States.
  • This is Currax Pharmaceuticals’ 1st transaction in California.

M&A Deal Summary

Date 2019-09-27
Target Nalpropion Pharmaceuticals
Sector Life Science
Buyer(s) Currax Pharmaceuticals
Deal Type Add-on Acquisition

Target

Nalpropion Pharmaceuticals

San Diego, California, United States
Nalpropion Pharmaceuticals, Inc. is a biopharmaceutical company focused on the treatment of weight loss. Nalpropion Pharmaceuticals was formed in 2018 and is based in San Diego, California.

Search 214,107 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try Free

Buyer(S) 1

Buyer

Currax Pharmaceuticals

Morristown, New Jersey, United States

Category Company
Sector Life Science
DESCRIPTION

Currax Pharmaceuticals LLC is a specialty pharmaceutical business focused on acquiring and commercializing prescription drugs within the U.S. market. Currax distributes a range of both Branded and generic pharmaceutical products, including Silenor®, Treximet®, Zohydro® ER with BeadTek® and the authorized generic of Treximet®.


DEAL STATS #
Overall 2 of 2
Sector: Life Science M&A 2 of 2
Type: Add-on Acquisition M&A Deals 2 of 2
State: California M&A 1 of 1
Country: United States M&A 2 of 2
Year: 2019 M&A 2 of 2
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2019-05-01 Pernix Therapeutics Holdings

Morristown, New Jersey, United States

Pernix Therapeutics Holdings, Inc. is a pharmaceutical company developing branded and generic pediatric products. Pernix Therapeutics was founded in 1996 and is based in Morristown, New Jersey.

Buy $76M